CIK 0001549595
- Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270838048
- Phone
- +1 415-660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 50 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-05 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 | +400 | $1.86 | $744 | 20,238 |
| 2024-06-05 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −400 | $17.00 | $7K | 19,838 |
| 2024-06-05 | Ring Christine Chief Legal Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −400 | 98,070 | ||
| 2024-06-03 | Ring Christine Chief Legal Officer | Option exercise 10b5-1 | +1,596 | $1.86 | $3K | 21,434 |
| 2024-06-03 | Ring Christine Chief Legal Officer | Sale 10b5-1 | −1,596 | $17.01 | $27K | 19,838 |
| 2024-06-03 | Ring Christine Chief Legal Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,596 | 98,470 | ||
| 2024-05-20 | Silva Paul M Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-20 | Kunkel Lori Anne Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-20 | GREGORY JULIA P Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-20 | Lacey David L. Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-20 | Reinsdorf Judith A Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-20 | Saltzman Edward C Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-05-02 | van Houte Hans Chief Financial Officer | Sale 10b5-1 | −3,499 | $12.83 | $45K | 68,333 |
| 2024-04-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,886 | 71,219 | ||
| 2024-04-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,000 | 73,219 | ||
| 2024-04-30 | van Houte Hans Chief Financial Officer | Sale | −1,387 | $12.04 | $17K | 71,832 |
| 2024-04-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −2,886 | 20,203 | ||
| 2024-04-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −2,000 | 16,000 | ||
| 2024-04-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +3,206 | 39,608 | ||
| 2024-04-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +2,000 | 41,608 |
Page 21 of 32 · 632 trades